Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
42.58
-0.11 (-0.26%)
Streaming Delayed Price
Updated: 10:53 AM EDT, May 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about GeneDx Holdings Corp. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
May 06, 2026
One of these stocks plummeted 49% on Tuesday.
Via
The Motley Fool
Topics
Initial Public Offering
Keep an eye on the top gainers and losers in Tuesday's session.
↗
May 05, 2026
Via
Chartmill
Why GeneDX Stock Is Plummeting Today
↗
May 05, 2026
GeneDX's latest quarterly report arrived with a lot of bad news for investors.
Via
The Motley Fool
Which stocks are gapping on Tuesday?
↗
May 05, 2026
Via
Chartmill
GeneDx Holdings Corp (NASDAQ:WGS) Plunges 44% After Disastrous Q1 2026 Miss
↗
May 04, 2026
Via
Chartmill
GeneDx Holdings Corp (NASDAQ:WGS) Reports Mixed Q4 2025 Results, Stock Falls Despite Strong 2026 Outlook
↗
February 23, 2026
Via
Chartmill
Wondering what's happening in today's pre-market session?
↗
May 05, 2026
Via
Chartmill
GeneDx (WGS) Q1 2026 Earnings Transcript
↗
May 04, 2026
GeneDx (WGS) Q1 2026 Earnings Transcript
Via
The Motley Fool
Top movers in Monday's after hours session
↗
May 04, 2026
Via
Chartmill
GeneDx (WGS) Q1 2025 Earnings Call Transcript
↗
May 04, 2026
GeneDx (WGS) Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
GeneDx (WGS) Q2 2025 Earnings Transcript
↗
May 04, 2026
GeneDx (WGS) Q2 2025 Earnings Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
April 08, 2026
Three stocks that have fallen more than 23% this year were on the Ark Invest CEO's shopping radar on Tuesday.
Via
The Motley Fool
Topics
ETFs
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
↗
March 10, 2026
Ark Invest's CEO kicked off the new trading week with a little shopping.
Via
The Motley Fool
Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million
↗
February 27, 2026
Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.
Via
The Motley Fool
Topics
Regulatory Compliance
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million
↗
February 27, 2026
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
Via
The Motley Fool
Topics
Regulatory Compliance
What a $75 Million Exit From MDU Might Signal Amid a 24% One-Year Rally
↗
February 26, 2026
MDU Resources Group supplies regulated utilities and construction services across the U.S., with consistent revenue and a stable dividend.
Via
The Motley Fool
Topics
Energy
GeneDx's Chief Operating Officer Sold Nearly 6,000 Shares. Is the Stock a Buy or Sell?
↗
February 26, 2026
AI-powered health intelligence firm GeneDx Holdings reported a notable insider sale as it advances its clinical data analytics platform.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
GeneDx (WGS) Q4 2025 Earnings Call Transcript
↗
February 23, 2026
GeneDx (WGS) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Artificial Intelligence
Earnings
Power Solutions Stock Up 140% as $6.36 Million Exit Follows 62% Sales Surge
↗
February 16, 2026
Power Solutions International designs and manufactures advanced engines and power systems for industrial and transportation markets.
Via
The Motley Fool
Topics
Energy
Regulatory Compliance
Freshworks Falls 60% in a Year as $7.5 Million Sale Shrinks Stake to 3.1% of This Portfolio's Assets
↗
February 16, 2026
This SaaS firm delivers cloud-based business software worldwide, focusing on subscription-driven customer and IT service solutions.
Via
The Motley Fool
Topics
Regulatory Compliance
Air Lease Stock Up 43% as Investor Trims $6.9 Million Stake Despite $1 Billion Profit Year
↗
February 16, 2026
Air Lease Corporation provides global airlines with commercial jet leasing, sales, and fleet management services across a diverse portfolio.
Via
The Motley Fool
Topics
Regulatory Compliance
Five9 Stock Down 60% This Past Year, but One Investor Just Lifted Stake With $3.5 Million Buy
↗
February 16, 2026
Five9 delivers cloud-based contact center software for enterprises, serving clients across finance, healthcare, and technology sectors.
Via
The Motley Fool
Freshworks Stock Down 60% in One Year as Revenue Jumps 16% and One Investor Sells $7 Million in Shares
↗
February 16, 2026
Freshworks delivers cloud-based SaaS solutions for customer engagement, IT service management, and business process automation.
Via
The Motley Fool
Topics
Regulatory Compliance
The Great Rotation: Small-Caps Stand Tall as AI Exhaustion Triggers Tech Rout
January 29, 2026
The stark divide in the financial markets reached a fever pitch today, January 29, 2026, as the long-anticipated "Great Rotation" finally appeared to take hold. While the tech-heavy Nasdaq Composite...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
The Great Rotation of 2026: Why Wall Street is Abandoning Big Tech for Main Street Small Caps
January 28, 2026
The dawn of 2026 has brought a seismic shift to global equity markets, as the long-anticipated "Great Rotation" finally takes hold. After nearly three years of dominance by a handful of mega-cap...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
The Great AI Pivot: From Massive Build-Out to the Era of Operational ROI
January 27, 2026
As of January 27, 2026, the global financial markets are witnessing a profound transformation in the artificial intelligence narrative. While 2023 and 2024 were defined by a "land grab" for...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Workforce
The Great Rotation: Wall Street’s ‘Earnings Handoff’ Moves from Silicon Valley to Main Street
January 26, 2026
As of January 26, 2026, the financial landscape has undergone a seismic shift, marking the definitive end of the "Magnificent 7" era of uncontested dominance. For the first time in decades, the baton...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Earnings
The Great Rotation: Small-Caps Set to Outpace ‘Magnificent 7’ in Historic Earnings Handoff
January 26, 2026
As of January 26, 2026, the long-standing hierarchy of the U.S. equity markets is undergoing its most significant transformation since the post-pandemic recovery. For the first time in years, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
↗
January 25, 2026
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.
Via
The Motley Fool
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy?
↗
January 24, 2026
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today